Holen Sie sich die Stockscreener-App
46.96
0.70%
-0.33
Schlusskurs vom Vortag:
$47.29
Offen:
$46.22
24-Stunden-Volumen:
464.32K
Relative Volume:
0.54
Marktkapitalisierung:
$3.10B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-15.15
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
-1.39%
1M Leistung:
+50.80%
6M Leistung:
+11.46%
1J Leistung:
+34.67%
1-Tages-Spanne:
$46.04
$47.33
1-Wochen-Bereich:
$45.80
$50.27
52-Wochen-Spanne:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
46.96 | 3.10B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN
Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - MSN
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? - Benzinga
B. Riley Research Analysts Lower Earnings Estimates for KYMR - Defense World
Top 10 NASDAQ Stocks with Strong Growth Potential by Kalkine - Kalkine Media
Ameriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst - Defense World
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Overweight” at Morgan Stanley - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to “Buy” Rating - Defense World
B. Riley Securities Upgrades Kymera Therapeutics (KYMR) - Nasdaq
Kymera Therapeutics Executives and Directors Sell Shares - TradingView
Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race - insights.citeline.com
Kymera stock draws upgrades after trial data (KYMR:NASDAQ) - Seeking Alpha
Morgan Stanley upgrades Kymera stock rating, raises price target By Investing.com - Investing.com Canada
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - TradingView
Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - marketscreener.com
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Ta - GuruFocus
Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Target Boost | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Buy” at Bank of America - Defense World
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan - GuruFocus
What 6 Analyst Ratings Have To Say About Kymera Therapeutics - Nasdaq
Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Receives Upgraded Target Price and Po - GuruFocus
JPMorgan Raises Kymera Therapeutics (KYMR) Target Price Amid Positive Phase 1 Data | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Shares Boosted by Positive KT-621 Dat - GuruFocus
Wells Fargo reiterates overweight rating on Kymera Therapeutics stock By Investing.com - Investing.com UK
Where are the Opportunities in (KYMR) - news.stocktradersdaily.com
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - MSN
Kymera reports promising Phase 1 results for KT-621 By Investing.com - Investing.com South Africa
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - MSN
These 10 Stocks Blew Past Expectations - Insider Monkey
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I - Genetic Engineering and Biotechnology News
Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgra - GuruFocus
Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgrade | KYMR Stock News - GuruFocus
Kymera, with new data, takes early step toward a Dupixent-like pill - BioPharma Dive
TRUIST SECURITIES MAINTAINS BUY RATING ON KYMERA STOCK AFTER POSITIVE STUDY RESULTS - Investing.com UK
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data (NASDAQ:KYMR) - Seeking Alpha
Citi Increases Price Target for Kymera Therapeutics (KYMR) to $6 - GuruFocus
Citi Increases Price Target for Kymera Therapeutics (KYMR) to $60 | KYMR Stock News - GuruFocus
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):